ArticleClinical journal of the American Society of Nephrology : CJASN2011
Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Heart failure in patients with chronic kidney disease: a systematic integrative review.BioMed research international · 2014Pooled it
- Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Renal denervation revisited: is patient selection the missing link between failure and success?Clinical hypertension · 2026Review
- Hidden Impacts of Peritoneal Dialysis on the Endocrine System.Life (Basel, Switzerland) · 2025Review
- The autonomic nervous system and bone health in chronic kidney disease.European journal of clinical investigation · 2025Review
- Impaired Neurocirculatory Control in Chronic Kidney Disease: New Evidence for Blunted Sympathetic Baroreflex and Reduced Sympathetic Transduction.Function (Oxford, England) · 2024Article
- Impact of Impaired Kidney Function on Arrhythmia-Promoting Cardiac Ion Channel Regulation.International journal of molecular sciences · 2023Review
- Uremic toxins in chronic kidney disease highlight a fundamental gap in understanding their detrimental effects on cardiac electrophysiology and arrhythmogenesis.Acta physiologica (Oxford, England) · 2022Review
- Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021Article
- Effect of a Low Dose of Carvedilol on Cyclophosphamide-Induced Urinary Toxicity in Rats-A Comparison with Mesna.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Clinical Relevance of the Sympathetic-Vascular Interactions in Health and Disease.Biomedicines · 2021Review
- Haemodialysis and peritoneal dialysis patients have severely impaired post-occlusive skin forearm vasodilatory response assessed with laser speckle contrast imaging.Clinical kidney journal · 2021Article
- Intracranial baroreflex is attenuated in an ovine model of renovascular hypertension.Scientific reports · 2021Article
- Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation.Current hypertension reports · 2021Review
- Nutraceuticals as a potential adjunct therapy toward improving vascular health in CKD.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Review
- Relation of neuropeptide Y gene expression and genotyping with hypertension in chronic kidney disease.Biochemistry and biophysics reports · 2019Article
- The role of increased glucose on neurovascular dysfunction in patients with the metabolic syndrome.Journal of clinical hypertension (Greenwich, Conn.) · 2017Article
- Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms.International journal of molecular sciences · 2017Review
- The systemic nature of CKD.Nature reviews. Nephrology · 2017Review
- Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.Current hypertension reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSympathetic overactivity and high levels of the endogenous inhibitor of NO synthase asymmetric dimethylarginine (ADMA) are prevalent risk factors in chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In 48 stage 2 to 4 CKD patients, we investigated the relationship between efferent postganglionic muscle sympathetic nerve traffic (microneurography) and circulating ADMA and analyzed the links between these risk factors and estimated GFR (eGFR), proteinuria, and different parameters of left ventricular (LV) geometry.
resultsCKD patients characterized by sympathetic nerve traffic values in the third tertile showed the highest ADMA levels, and this association was paralleled by a continuous, positive relationship between these two risk factors (r = 0.32, P = 0.03) independent of other confounders. Both sympathetic nerve traffic and ADMA were inversely related to eGFR and directly to proteinuria and LV geometry. Remarkably, the variance of eGFR, proteinuria, and LV geometry explained by sympathetic nerve traffic and ADMA largely overlapped because sympathetic nerve traffic but not ADMA was retained as a significant correlate of the eGFR (P < 0.001) and of the relative wall thickness or the left ventricular mass index/LV volume ratio (P = 0.05) in models including both risk factors. ADMA, but not sympathetic nerve traffic, emerged as an independent correlate of proteinuria (P = 0.003) in a model including the same covariates.
conclusionsSympathetic activity and ADMA may share a pathway leading to renal disease progression, proteinuria, and LV concentric remodeling in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.